Corcept Therapeutics Incorporated - Asset Resilience Ratio
Corcept Therapeutics Incorporated (CORT) has an Asset Resilience Ratio of 28.16% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Corcept Therapeutics Incorporated strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Corcept Therapeutics Incorporated's Asset Resilience Ratio has changed over time. See Corcept Therapeutics Incorporated balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Corcept Therapeutics Incorporated's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Corcept Therapeutics Incorporated.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $229.45 Million | 28.16% |
| Total Liquid Assets | $229.45 Million | 28.16% |
Asset Resilience Insights
- Very High Liquidity: Corcept Therapeutics Incorporated maintains exceptional liquid asset reserves at 28.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Corcept Therapeutics Incorporated Industry Peers by Asset Resilience Ratio
Compare Corcept Therapeutics Incorporated's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Corcept Therapeutics Incorporated (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Corcept Therapeutics Incorporated.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 30.08% | $251.66 Million | $836.65 Million | -0.34pp |
| 2024-12-31 | 30.42% | $255.67 Million | $840.55 Million | -7.02pp |
| 2023-12-31 | 37.44% | $232.67 Million | $621.52 Million | -25.18pp |
| 2022-12-31 | 62.62% | $365.34 Million | $583.43 Million | +28.19pp |
| 2021-12-31 | 34.43% | $145.92 Million | $423.76 Million | -29.32pp |
| 2020-12-31 | 63.75% | $364.51 Million | $571.73 Million | +4.41pp |
| 2019-12-31 | 59.35% | $244.69 Million | $412.31 Million | +6.37pp |
| 2018-12-31 | 52.98% | $165.13 Million | $311.69 Million | +26.82pp |
| 2017-12-31 | 26.16% | $57.68 Million | $220.54 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $68.75 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $51.94 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $34.63 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $63.08 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $99.17 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $39.83 Million | -- |
| 2008-12-31 | 18.17% | $3.59 Million | $19.77 Million | -15.27pp |
| 2007-12-31 | 33.44% | $5.93 Million | $17.74 Million | +27.88pp |
| 2006-12-31 | 5.55% | $550.00K | $9.90 Million | -78.22pp |
| 2005-12-31 | 83.78% | $25.26 Million | $30.16 Million | +17.90pp |
| 2004-12-31 | 65.88% | $31.47 Million | $47.77 Million | +53.11pp |
| 2003-12-31 | 12.77% | $1.50 Million | $11.78 Million | -1.65pp |
| 2002-12-31 | 14.42% | $3.14 Million | $21.80 Million | -- |
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type … Read more